Osimertinib With Chemo Gains FDA Approval for EGFR-Mutated NSCLC
Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.
Source: ajmc.com
Page 8 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC
A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.
Source: onclive.com
Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC
Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.
Source: onclive.com
FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC
The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.
Source: ajmc.com
FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations
The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.
Source: onclive.com